Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

Inclusion Criteria: * aged over 18 years * diagnosed with immune thrombocytopenia (bone marrow examination is not necessary) * failed to achieve platelet count over 50X10\^9/L with eltrombopag * ECOG performance status 0,1,2 * available to obtain informed consent Exclusion Criteria: * Hepatitis B or C carriers * HIV positive patients * diagnosed with systemic lupus erythematosus or other autoimmune disorders * unable to intake orally or absorb through gastrointestinal tract * pregnant or breast-feeding * diagnosed with uncontrolled seizure or other neuropsychiatric disorders * diagnosed with clinically significant cardiovascular events within 6 months or dyspnea on exertion evaluated to New York Heart Association Functional Classification III or IV * diagnosed with clinically significant cerebrovascular disorders * previously diagnosed or treated with thromboembolism * current treating malignant diseases * currently accompanied by uncontrolled infection or active bleeding * with blood test results as follows; total bilirubin \> 2xUNL(upper normal limit), AST/ALT \> 1.5xUNL, creatinine \> 1.5xUNL, glomerular filtration rate \< 30ml/min/1.73m\^2 * registered to other clinical trials for treatment of immune thrombocytopenia * judged to be inappropriate for clinical trial by doctor in charge